1. Hong Kong Stocks

  2. •

    Process industries

  3. •

    Industrial specialties
Good Fellow Healthcare Holdings Limited TEMP

Good Fellow Healthcare Holdings Limited TEMP

0.27
HKD
0.00
(0.00%)
-0.01EPS
Good Fellow Healthcare Holdings Limited TEMP
HKEX:8567
(Hong Kong Exchange)

Recent

price

0.27

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
HKD
5.14
5.67
6.24
5.36
5.81
0.58
0.5
0.54
0.45
0.2
0.07
0.07
0.08
0.05
0.02
0.5
0.1
Revenue per Share
0.11
0.15
0.13
0.05
-1.65
-0.1
0.01
-0.17
-0.07
-0.07
-0.04
-0.02
-0.01
-0.02
-0.02
-0.31
-0.01
Basic EPS, GAAP
-0.09
0.18
-0.13
0.03
-0.07
0.32
-0.2
0.01
0.01
-0.07
-0.03
-0.03
-0.01
-0.02
- -
-0.2
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.58
2.78
3.18
2.29
0.49
0.41
0.4
0.28
0.18
0.11
0.06
0.04
0.03
0.01
-0.01
0.01
0.02
Book Value per Share
0.15
0.34
0.53
-0.2
0.42
0.35
0.12
0.17
0.15
0.1
0.05
0.04
0.03
0.01
-0.01
0.01
0.02
Tangible Book Value per Share
285
324
324
418
306
436
536
612
728
728
728
728
728
728
658
40
553
Basic Weighted Avg Shares
1,464
1,836
2,021
2,243
1,780
253
270
330
327
145
54
54
55
39
16
20
53
Sales/Revenue/Turnover
4.8
4.94
3.95
3.85
1.02
-10.59
2.11
3.19
-3.45
-26.52
-70.38
-61.7
-17.74
-26.03
-67.52
-65.64
-18.7
Operating Margin (%)
12
10
11
11
15
19
22
20
23
26
14
10
7
6
9
- -
- -
Depreciation Expense
31
50
43
22
-506
-43
10
-103
-50
-50
-30
-13
-6
-17
-10
-13
-6
Net Income, GAAP
36.66
31.25
30.46
43.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
2.15
2.71
2.12
0.98
-28.4
-17.15
3.79
-31.09
-15.4
-34.24
-56.01
-23.4
-10.62
-43.91
-62.82
-62.43
-11.93
Profit Margin (%)
217
276
319
363
318
389
71
129
109
40
19
11
7
-17
-8
7
-11
Working Capital
198
202
197
76
78
157
33
41
- -
15
16
5
2
2
- -
- -
3
LT Debt
877
940
986
1,150
381
394
288
251
148
72
33
26
19
1
-7
8
11
Total Equity
4.11
5.67
4.74
3.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
3.07
4.26
3.49
0.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
4.08
5.72
4.64
2.63
-106.88
-21.48
1.69
-46.27
-30.31
-47.32
-51.31
-36.35
-22.71
-128.9
- -
- -
-35.37
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Mar'23
Jun'24
Sep'24
ST Debt
2
- -
2
LT Borrowings
- -
- -
2
LT Finance Leases
2
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
728
728
728
Market Capitalization
- -
- -
- -

Working Capital

HKD

•

in mil. unless spec.
Mar'23
Jun'24
Sep'24
Total Current Assets
27
- -
9
Cash, Cash Equivalents & STI
18
- -
5
Accounts Receivable, Net
- -
- -
- -
Inventories
2
- -
1
Total Current Liabilities
20
- -
19
Payables & Accruals
- -
- -
- -
ST Debt
2
- -
2
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-112.25%
-187.19%
-216.71%
Free Cash Flow
-149.97%
-60.84%
-418.13%
Net Income, GAAP
-125.95%
12.44%
23.66%
Sales/Revenue/Turnover
-15.15%
-12.22%
24.44%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
39
2025
- -
- -
16
2026
- -
- -
20

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
-0.02
2026
- -
- -
-0.31

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Asian Paints Ltd. (NSE:ASIANPAINT)
Solar Industries India Limited (NSE:SOLARINDS)
Berger Paints India Limited (NSE:BERGEPAINT)
Fineotex Chemical Limited (NSE:FCL)
Graphite India Limited (NSE:GRAPHITE)
Srf Limited (NSE:SRF)
Business
Good Fellow Healthcare Holdings Limited is an investment holding company principally engaged in the operation and management of hospitals, primarily in Mainland China and Hong Kong. Its core products and services include comprehensive general hospital services such as medical wards, surgical wards, cosmetic surgery, dermatology, medical checkup and examination services. The company also provides medical investment, hospital management services, and diversified hospital operation management solutions through mergers and acquisitions, management consultation, special projects planning, professional training, and entrusted management. It targets a wide range of healthcare markets and operates general hospitals with a focus on developing comprehensive secondary hospitals and specialist chain hospitals to build a competitive medical service network. The company was incorporated in 2001, is headquartered in Central, Hong Kong, and is a subsidiary of Solar Star Global Limited. Good Fellow Healthcare actively introduces advanced foreign medical technology, management models, and service concepts, partnering with multiple medical colleges, scientific research institutions, and expert teams across China and internationally to support difficult disease consultation, surgery, and clinical research. The company has developed a distinctive "Good Fellow Model" recognized for its effective hospital management, cost control, and service positioning adapted to China's healthcare environment. In the last 1-2 years, Good Fellow Healthcare Holdings Limited undertook strategic expansions and operational adjustments including issuing 564 million rights shares in mid-2025 to strengthen its capital base. Despite facing operational losses reported in fiscal periods ending in 2025, the company continues to focus on expanding its hospital network and enhancing its medical technology and service offerings. Good Fellow Healthcare's latest initiatives involve deepening its hospital integration and construction efforts alongside leveraging expert-led medical research and specialized medical technologies to sustain long-term growth and competitive differentiation in the healthcare sector. This profile reflects Good Fellow Healthcare Holdings Limited's comprehensive role in hospital operations, medical investment, and healthcare service innovation within China and its ongoing efforts to consolidate and expand its footprint in the domestic medical and health industry market.